ĐẶC ĐIỂM BỘC LỘ CÁC DẤU ẤN WT1, P53, P16 VÀ MỐI LIÊN QUAN VỚI ĐỘ MÔ HỌC Ở NGƯỜI BỆNH UNG THƯ BIỂU MÔ THANH DỊCH BUỒNG TRỨNG TẠI BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG GIAI ĐOẠN 2020-2024

Abstract

Study of 74 cases of primary ovarian cancer undergoing oophorectomy with a histopathological diagnosis of serous carcinoma at the National Hospital of Obstetrics and Gynecology during the period from January 2020 to March 2024 . Regular HE staining and histopathological classification according to the WHO 2020 classification. Immunohistochemical staining evaluates the expression of markers WT1, p53, p16 on ovarian serous carcinoma using the ABC method. Results and conclusions: Regarding the characteristics of the markers WT1, p53, p16: high-grade serous carcinoma has a relatively high positive rate for WT1 (96.5%), positive (3+) accounts for a high rate highest (52.8%), positive (2+) accounts for a lower rate of 24.3%. Positive (4+) and (+) account for 12.9% and 10%, respectively. Low-grade serous carcinomas had a lower WT1 positivity rate (88.2%). The positive rate for p53 is 100%. Of these, 97.3% were positive for the wild type and 2.7% were positive for no phenotype (null phenotype). Positive (4+) for p53 accounts for the highest rate (41.7%). Positive (+) accounts for a lower rate of 26.4%. Positive (2+) and (3+) accounted for 18.1% and 13.8%, respectively. The positive rate for p16 is 100%. Positive (4+) for p16 was highest (41.3%). Positive (3+) accounts for a lower rate of 31.1%. Positive (2+) is 12.2% and the lowest rate is positive (+) is 5.4%. Regarding the relationship between the expression level of markers WT1, p53, p16 and the histological grade of ovarian serous carcinoma: high-grade serous carcinoma is positive (3+) for WT1 (54, 1%), positive (4+) for p53 (53.3%), and most positive (4+) for p16 (60.5%). The expression level of WT1, p53, and p16 in low-grade serous carcinomas is lower than that of other types. However, this difference is not statistically significant with p > 0.05. The research results were compared and discussed.